This small local medical devices company has an FDA approved patented on-site blood testing machine + renewable reagents in a disc. One for humans and one for animals, already being marketed under marketing agreements with major companies. And the blood testing market is huge. The company can make money like a razor blade company makes money, i.e. by selling more discs. What more can one expect in a new company? Yet its stock(some of which I own) moves but little.
Surely this must be one of the market inefficiencies I keep reading about. Comments solicited. Note that the stock is recommended in Murphy's CTSL newletter. |
